A Rare B-Myeloid Conversion of Follicular Lymphoma into Clonally Related Acute Myeloid Leukemia: A Case Report

Follicular lymphoma (FL) is a highly prevalent indolent lymphoma, and the risk of histological transformation is approximately 2–3% per year. Transformation of FL generally occurs in the same lineage (B cell lineage). Another rare form of disease progression is the transformation of neoplastic B-cells to another cell lineage such as acute myeloid leukemia (AML). The low incidence of B-myeloid transformation associated with poor prognosis hinders the establishment of model systems to identify molecular mechanisms. A 64-year-old woman was diagnosed with FL and achieved a satisfactory response after six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Approximately one month after treatment terminated, the disease progressed to AML with an increased white blood cell count and abnormal coagulation. Interestingly, nucleotide sequence analysis of the genomic region encoding the immunoglobulin heavy-chain variable domain showed the possibility of homologous transformation from lymphoma to leukemia cells. Although the patient experienced transient improvement after undergoing treatment with one cycle of idarubicin and cytarabine combined with etoposide, she relapsed and died 8 days after venetoclax salvage therapy. Patient with B-myeloid transformation was associated with an aggressive clinical course and poor prognosis. Conventional strategies for treating histologically transformed AML were ineffective. However, treatment with a Bcl-2 inhibitor could serve as an option. Here we review the literature relevant to this rare histological transformation of FL.

[1]  A. Hui,et al.  Role of Biomarkers in FLT3 AML , 2022, Cancers.

[2]  Hongtao Liu Emerging agents and regimens for AML , 2021, Journal of Hematology & Oncology.

[3]  A. López-Guillermo,et al.  Follicular lymphoma , 2019, Nature Reviews Disease Primers.

[4]  C. Jordan Can we selectively target AML stem cells? , 2019, Best practice & research. Clinical haematology.

[5]  A. Feldman,et al.  Coactivation of NF-κB and Notch signaling is sufficient to induce B cell transformation and enables B-myeloid conversion. , 2019, Blood.

[6]  Xiaomei Ma,et al.  Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. , 2019, Blood reviews.

[7]  G. Salles,et al.  Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. , 2019, Blood.

[8]  P. Barr,et al.  How I treat early-relapsing follicular lymphoma. , 2019, Blood.

[9]  A. Wei,et al.  Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Medeiros,et al.  Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults , 2019, Annals of Hematology.

[11]  Michael R. Green,et al.  Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma , 2019, bioRxiv.

[12]  Anxun Wang,et al.  Up-regulation of INSR/IGF1R by C-myc promotes TSCC tumorigenesis and metastasis through the NF-κB pathway. , 2018, Biochimica et biophysica acta. Molecular basis of disease.

[13]  A. Letai,et al.  Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. , 2018, The Lancet. Oncology.

[14]  B. Darbro,et al.  Leukemic Transdifferentiation of Follicular Lymphoma Into an Acute Histiocytic Leukemia in a 52-Year-Old Caucasian Woman , 2016, Laboratory medicine.

[15]  Michael R Green,et al.  miR-146a promotes the initiation and progression of melanoma by activating Notch signaling , 2014, eLife.

[16]  Denis Thieffry,et al.  C/EBPα poises B cells for rapid reprogramming into induced pluripotent stem cells , 2013, Nature.

[17]  T. Graf,et al.  Stepwise Reprogramming of B Cells into Macrophages , 2004, Cell.